HER2 Mutation-Related Tumors

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Iambic Therapeutics
Iambic TherapeuticsCA - San Diego
1 program
1
IAM1363Phase 11 trial
Active Trials
NCT06253871Recruiting243Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Iambic TherapeuticsIAM1363

Clinical Trials (1)

Total enrollment: 243 patients across 1 trials

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Start: Mar 2024Est. completion: Mar 2028243 patients
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 243 patients
1 companies competing in this space